Parameter Number (%)
Age, years Range (mean ± SD)
39-85 (65.5 ± 10.3)
Sex Male Female 24 (57.1) 18 (42.9)
Underlying malignancy Cutaneous Melanoma Merkel cell carcinoma Cutaneous SCC of head and neck Sebaceous carcinoma Lung Sq NSCLC Non-Sq NSCLC Gastrointestinal Esophageal SCC Gastric adenocarcinoma Genitourinary Renal cell carcinoma Urothelial carcinoma 17 (40.5) 12 (28.6) 1 (2.4) 3 (7.1) 1 (2.4) 17 (40.5) 7 (16.7) 10 (23.8) 3 (7.1) 2 (4.8) 1 (2.4) 5 (11.9) 4 (9.5) 1 (2.4)
Immune checkpoint inhibitors Nivolumab Pembrolizumab Ipilimumab Nivolumab + ipilimumab Atezolizumab Avelumab 18 (45.0) 10 (25.0) 2 (5.0) 5 (12.5) 3 (7.5) 2 (5.0)
Total 40 (100.0)